Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy

Zhou, Xu; Liu, Renhe; Qin, Shucheng; Yu, Ruilian; Fu, Yao

doi:10.2174/1389200217666160714095722

Cited by 13 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past years, treatments that target and kill cancer cells by using or strengthening the immune system of patients have been developed (7,8), with antibodies targeting inhibitory signaling molecules expressed on immune and tumor cells being commonly used treatment modalities (9,10). Typical targets include cytotoxic T-lymphocyte associated protein 4 (CTLA4) and the immune checkpoint proteins programmed death-1 (PD-1), and PD-1 ligand (PD-L1) (11).…”

Section: Introductionmentioning

confidence: 99%

CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer

Zhang

et al. 2020

Cancer Letters

View full text Add to dashboard Cite

Background: The T cell response against different tumors is improved by immunogenic cell death (ICD), indicating a role for ICD in augmenting antitumor immunity elicited by the anti-checkpoint antibody antiprogrammed death 1 (anti-PD-1). Methods: The effect of SR-4835 on breast cancer was analyzed by cell proliferation and ow cytometry. Calreticulin translocation and HMGB1 and ATP release were detected by ow cytometry, ELISA and luminescence assay, respectively. Immunogenicity in vitro was analyzed by co-culturing of SR-4835 treated cancer cells with bone-marrow derived dendritic cells (BMDCs) and rate of maturation of BMDCs and production of IL-6 in the supernatant were measured. The in vivo antitumor effect was analyzed by syngeneic mouse model followed by ow cytometry for TILs. Results: In the present study, we report a synergistic and durable immune-mediated antitumor response elicited by the combined treatment of SR-4835, a CDK12/13 speci c inhibitor, with PD-1 blockade in a murine model of 4T1 breast cancer. The developed combination therapy elicited antitumor activity in immunocompetent mouse tumor models. Furthermore, the SR-4835-treated tumor cells exhibited characteristics of ICD, including the release of high mobility group box 1 (HMGB1) and ATP and the translocation of surface calreticulin (CRT). This activity led to a significant T-cell dependent regression of tumors. The enhanced in ltration of T cells and dendritic cell (DC) activation in the tumors of mice treated with both SR-4835 and anti-PD-1 indicate that this combination treatment promotes an improved immune response and suggests a potential mechanism involving anti-PD-1 and SR-4835 activity that enhances anti-PD-1 effects. Conclusion: The results of the present study demonstrate the potential of CDK12/13 inhibition combined with checkpoint inhibition in breast cancer treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer

Zhang

et al. 2020

Cancer Letters

View full text Add to dashboard Cite

show abstract

“…Targeted cancer therapy remains a major challenge in the eradication of tumors. Drug delivery systems using nanoparticles offer a novel approach to specifically delivering drugs to cancer cells while sparing normal cells [1][2][3][4]. Glioblastoma multiforme (GBM) is the most frequent malignant primary brain tumor representing 32% of all brain tumor cases in adults, and 81% of malignant tumors [5].…”

mentioning

confidence: 99%

Magnetoelectric Nanoparticles for Delivery of Antitumor Peptides Into Glioblastoma Cells By Magnetic Fields

Stewart

Nagesetti

Guduru

et al. 2018

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…An excellent carrier is born at the right moment, and AuNPs have proven to be competent for the job because of the properties of AuNPs (such as the biocompatibility and nontoxicity of gold) ( Zhou et al, 2016a ). They show better performance than other nanoparticulate-based carriers; for example, their size is easily controlled for different applications, and the majority of antigens and adjuvants can be easily connected to and displayed on their surface.…”

Section: The Application Of Aunps In Cancer Immunotherapymentioning

confidence: 99%

The Application of and Strategy for Gold Nanoparticles in Cancer Immunotherapy

Liu

Zhang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Immunotherapy of malignant tumor is a verified and crucial anti-tumor strategy to help patients with cancer for prolonging prognostic survival. It is a novel anticancer tactics that activates the immune system to discern and damage cancer cells, thereby prevent them from proliferating. However, immunotherapy still faces many challenges in view of clinical efficacy and safety issues. Various nanomaterials, especially gold nanoparticles (AuNPs), have been developed not only for anticancer treatment but also for delivering antitumor drugs or combining other treatment strategies. Recently, some studies have focused on AuNPs for enhancing cancer immunotherapy. In this review, we summarized how AuNPs applicated as immune agents, drug carriers or combinations with other immunotherapies for anticancer treatment. AuNPs can not only act as immune regulators but also deliver immune drugs for cancer. Therefore, AuNPs are candidates for enhancing the efficiency and safety of cancer immunotherapy.

show abstract

Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy

Cited by 13 publications

References 0 publications

CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer

CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer

Magnetoelectric Nanoparticles for Delivery of Antitumor Peptides Into Glioblastoma Cells By Magnetic Fields

The Application of and Strategy for Gold Nanoparticles in Cancer Immunotherapy

Contact Info

Product

Resources

About